Aktis Oncology (NASDAQ:AKTS) Stock Has Average Price Target of $35.62 According to Brokerages

Shares of Aktis Oncology (NASDAQ:AKTS) have been given an average rating of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $35.62.

A number of research analysts have recently issued reports on AKTS shares. BMO Capital Markets initiated coverage on Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price on the stock. HC Wainwright lifted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Wedbush started coverage on shares of Aktis Oncology in a research report on Wednesday, August 19th. They issued an “outperform” rating and a $35.00 price target on the stock. Oppenheimer started coverage on Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Raymond James Financial began coverage on Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target for the company.

Insider Activity

In related news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the sale, the director directly owned 3,506 shares in the company, valued at approximately $86,107.36. This trade represents a 58.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Aktis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of AKTS. State of Wyoming acquired a new position in Aktis Oncology in the second quarter worth $32,000. AXQ Capital LP acquired a new position in Aktis Oncology during the 2nd quarter worth $226,000. Susquehanna International Group LLP acquired a new position in Aktis Oncology during the 2nd quarter valued at about $278,000. Deutsche Bank AG lifted its position in Aktis Oncology by 49.3% in the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after purchasing an additional 6,942 shares during the period. Finally, Readystate Asset Management LP acquired a new stake in Aktis Oncology in the 2nd quarter valued at about $967,000. Institutional investors own 28.84% of the company’s stock.

Aktis Oncology Trading Down 0.5%

Shares of AKTS opened at $19.63 on Friday. The firm has a market capitalization of $1.06 billion and a price-to-earnings ratio of -23.94. The firm’s fifty day simple moving average is $24.07 and its 200-day simple moving average is $22.15. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. On average, analysts predict that Aktis Oncology will post -1.82 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology, Inc is a clinical-stage biotechnology company focused on developing precision cancer treatments. The company’s research is centered on targeted alpha therapies, which are designed to deliver highly potent radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.

Aktis Oncology is developing a pipeline of investigational therapies for solid tumors and other cancers. Its programs are intended to use tumor-targeting molecules to selectively transport radioactive payloads to cancer cells, with the goal of improving treatment effectiveness and addressing cancers that may be difficult to treat with conventional approaches.

The company’s product candidates remain in development and are subject to clinical, regulatory and commercial risks.